Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma

David Hong, Simon Lunagomez, E. Edmund Kim, Jeffery H. Lee, Robert S. Bresalier, Stephen G. Swisher, Tsung Tse Wu, Jeffery Morris, Zhongxing Liao, Ritsuko Komaki, Jaffer A. Ajani

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

BACKGROUND. The value of baseline positron emission tomography (PET) for predicting overall survival (OS) or disease-free survival (DFS) is unclear in patients with nondistant metastatic (locoregional only) esophageal carcinoma. The authors tested the hypothesis that, in this setting, the number of PET abnormalities (NPA) would correlate with OS and DFS. METHODS. The authors of the current study analyzed patients with localized esophageal carcinoma (Stages II and III) who had a baseline PET and endoscopic ultrasonography (EUS) and were all treated with chemoradiotherapy followed by surgery. The standardized uptake value (SUV) of PET avid lesions were evaluated for: SUV of the primary, NPA, peak SUV, and total SUV. Correlations were performed with baseline EUS results, OS, DFS, and clinical and pathologic response. RESULTS. Forty-seven patients who underwent chemoradiotherapy followed by surgery were analyzed. Most patients had clinical Stage III cancer. NPA was significantly associated with OS (Cox model, P = 0.02; log-rank test, P = 0.04) and DFS (P = 0.04). Patients with NPA > 1 had a death hazard ratio of 4.49 (reference, NPA = 1). In a multivariate analysis, NPA was independently predictive of OS (P = 0.03). Alternatively, SUV of the primary tumor, peak SUV, total SUV, and EUS clinical stage did not correlate with the type of response, OS or DFS. CONCLUSIONS. Data from the current study suggest that for nondistant metastatic esophageal carcinoma, baseline PET can predict patient outcome. Baseline NPA (> 1), reflecting the regional nodal metastases, is an independent predictor of OS. Baseline PET may become a useful stratification factor in randomized trials and for individualizing therapy.

Original languageEnglish (US)
Pages (from-to)1620-1626
Number of pages7
JournalCancer
Volume104
Issue number8
DOIs
StatePublished - Oct 15 2005
Externally publishedYes

Fingerprint

Esophagogastric Junction
Positron-Emission Tomography
Carcinoma
Disease-Free Survival
Survival
Endosonography
Chemoradiotherapy
Proportional Hazards Models
Neoplasms
Multivariate Analysis
Neoplasm Metastasis

Keywords

  • Baseline positron emission tomography
  • Disease-free survival
  • Esophageal carcinoma
  • Non-distant metastases
  • Overall survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Hong, D., Lunagomez, S., Edmund Kim, E., Lee, J. H., Bresalier, R. S., Swisher, S. G., ... Ajani, J. A. (2005). Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma. Cancer, 104(8), 1620-1626. https://doi.org/10.1002/cncr.21356

Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma. / Hong, David; Lunagomez, Simon; Edmund Kim, E.; Lee, Jeffery H.; Bresalier, Robert S.; Swisher, Stephen G.; Wu, Tsung Tse; Morris, Jeffery; Liao, Zhongxing; Komaki, Ritsuko; Ajani, Jaffer A.

In: Cancer, Vol. 104, No. 8, 15.10.2005, p. 1620-1626.

Research output: Contribution to journalArticle

Hong, D, Lunagomez, S, Edmund Kim, E, Lee, JH, Bresalier, RS, Swisher, SG, Wu, TT, Morris, J, Liao, Z, Komaki, R & Ajani, JA 2005, 'Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma', Cancer, vol. 104, no. 8, pp. 1620-1626. https://doi.org/10.1002/cncr.21356
Hong, David ; Lunagomez, Simon ; Edmund Kim, E. ; Lee, Jeffery H. ; Bresalier, Robert S. ; Swisher, Stephen G. ; Wu, Tsung Tse ; Morris, Jeffery ; Liao, Zhongxing ; Komaki, Ritsuko ; Ajani, Jaffer A. / Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma. In: Cancer. 2005 ; Vol. 104, No. 8. pp. 1620-1626.
@article{dd1cdbbc22584f84857efa201c952871,
title = "Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma",
abstract = "BACKGROUND. The value of baseline positron emission tomography (PET) for predicting overall survival (OS) or disease-free survival (DFS) is unclear in patients with nondistant metastatic (locoregional only) esophageal carcinoma. The authors tested the hypothesis that, in this setting, the number of PET abnormalities (NPA) would correlate with OS and DFS. METHODS. The authors of the current study analyzed patients with localized esophageal carcinoma (Stages II and III) who had a baseline PET and endoscopic ultrasonography (EUS) and were all treated with chemoradiotherapy followed by surgery. The standardized uptake value (SUV) of PET avid lesions were evaluated for: SUV of the primary, NPA, peak SUV, and total SUV. Correlations were performed with baseline EUS results, OS, DFS, and clinical and pathologic response. RESULTS. Forty-seven patients who underwent chemoradiotherapy followed by surgery were analyzed. Most patients had clinical Stage III cancer. NPA was significantly associated with OS (Cox model, P = 0.02; log-rank test, P = 0.04) and DFS (P = 0.04). Patients with NPA > 1 had a death hazard ratio of 4.49 (reference, NPA = 1). In a multivariate analysis, NPA was independently predictive of OS (P = 0.03). Alternatively, SUV of the primary tumor, peak SUV, total SUV, and EUS clinical stage did not correlate with the type of response, OS or DFS. CONCLUSIONS. Data from the current study suggest that for nondistant metastatic esophageal carcinoma, baseline PET can predict patient outcome. Baseline NPA (> 1), reflecting the regional nodal metastases, is an independent predictor of OS. Baseline PET may become a useful stratification factor in randomized trials and for individualizing therapy.",
keywords = "Baseline positron emission tomography, Disease-free survival, Esophageal carcinoma, Non-distant metastases, Overall survival",
author = "David Hong and Simon Lunagomez and {Edmund Kim}, E. and Lee, {Jeffery H.} and Bresalier, {Robert S.} and Swisher, {Stephen G.} and Wu, {Tsung Tse} and Jeffery Morris and Zhongxing Liao and Ritsuko Komaki and Ajani, {Jaffer A.}",
year = "2005",
month = "10",
day = "15",
doi = "10.1002/cncr.21356",
language = "English (US)",
volume = "104",
pages = "1620--1626",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma

AU - Hong, David

AU - Lunagomez, Simon

AU - Edmund Kim, E.

AU - Lee, Jeffery H.

AU - Bresalier, Robert S.

AU - Swisher, Stephen G.

AU - Wu, Tsung Tse

AU - Morris, Jeffery

AU - Liao, Zhongxing

AU - Komaki, Ritsuko

AU - Ajani, Jaffer A.

PY - 2005/10/15

Y1 - 2005/10/15

N2 - BACKGROUND. The value of baseline positron emission tomography (PET) for predicting overall survival (OS) or disease-free survival (DFS) is unclear in patients with nondistant metastatic (locoregional only) esophageal carcinoma. The authors tested the hypothesis that, in this setting, the number of PET abnormalities (NPA) would correlate with OS and DFS. METHODS. The authors of the current study analyzed patients with localized esophageal carcinoma (Stages II and III) who had a baseline PET and endoscopic ultrasonography (EUS) and were all treated with chemoradiotherapy followed by surgery. The standardized uptake value (SUV) of PET avid lesions were evaluated for: SUV of the primary, NPA, peak SUV, and total SUV. Correlations were performed with baseline EUS results, OS, DFS, and clinical and pathologic response. RESULTS. Forty-seven patients who underwent chemoradiotherapy followed by surgery were analyzed. Most patients had clinical Stage III cancer. NPA was significantly associated with OS (Cox model, P = 0.02; log-rank test, P = 0.04) and DFS (P = 0.04). Patients with NPA > 1 had a death hazard ratio of 4.49 (reference, NPA = 1). In a multivariate analysis, NPA was independently predictive of OS (P = 0.03). Alternatively, SUV of the primary tumor, peak SUV, total SUV, and EUS clinical stage did not correlate with the type of response, OS or DFS. CONCLUSIONS. Data from the current study suggest that for nondistant metastatic esophageal carcinoma, baseline PET can predict patient outcome. Baseline NPA (> 1), reflecting the regional nodal metastases, is an independent predictor of OS. Baseline PET may become a useful stratification factor in randomized trials and for individualizing therapy.

AB - BACKGROUND. The value of baseline positron emission tomography (PET) for predicting overall survival (OS) or disease-free survival (DFS) is unclear in patients with nondistant metastatic (locoregional only) esophageal carcinoma. The authors tested the hypothesis that, in this setting, the number of PET abnormalities (NPA) would correlate with OS and DFS. METHODS. The authors of the current study analyzed patients with localized esophageal carcinoma (Stages II and III) who had a baseline PET and endoscopic ultrasonography (EUS) and were all treated with chemoradiotherapy followed by surgery. The standardized uptake value (SUV) of PET avid lesions were evaluated for: SUV of the primary, NPA, peak SUV, and total SUV. Correlations were performed with baseline EUS results, OS, DFS, and clinical and pathologic response. RESULTS. Forty-seven patients who underwent chemoradiotherapy followed by surgery were analyzed. Most patients had clinical Stage III cancer. NPA was significantly associated with OS (Cox model, P = 0.02; log-rank test, P = 0.04) and DFS (P = 0.04). Patients with NPA > 1 had a death hazard ratio of 4.49 (reference, NPA = 1). In a multivariate analysis, NPA was independently predictive of OS (P = 0.03). Alternatively, SUV of the primary tumor, peak SUV, total SUV, and EUS clinical stage did not correlate with the type of response, OS or DFS. CONCLUSIONS. Data from the current study suggest that for nondistant metastatic esophageal carcinoma, baseline PET can predict patient outcome. Baseline NPA (> 1), reflecting the regional nodal metastases, is an independent predictor of OS. Baseline PET may become a useful stratification factor in randomized trials and for individualizing therapy.

KW - Baseline positron emission tomography

KW - Disease-free survival

KW - Esophageal carcinoma

KW - Non-distant metastases

KW - Overall survival

UR - http://www.scopus.com/inward/record.url?scp=26444557983&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26444557983&partnerID=8YFLogxK

U2 - 10.1002/cncr.21356

DO - 10.1002/cncr.21356

M3 - Article

VL - 104

SP - 1620

EP - 1626

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 8

ER -